Treatment of chronic hepatitis C virus infection in patients with cirrhosis (Q34022678)

30 July 2017

1 reference

title

Treatment of chronic hepatitis C virus infection in patients with cirrhosis (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

1 reference

1 reference

Zeuzem S

1

1 reference

30 July 2017

1 September 2000

1 reference

Journal of Viral Hepatitis

30 July 2017

1 reference

30 July 2017

7

1 reference

30 July 2017

5

1 reference

30 July 2017

327-334

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Correlation between virus genotype and chronicity rate in acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon treatment of cirrhotic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Interferon-alpha in malignant and viral diseases. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Biological basis for the clinical use of interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Hepatitis C virus genotypes and development of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

HCV-associated liver cancer without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00229.X

10.1046/J.1365-2893.2000.00229.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10971820